Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.45 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446429 | 0.85 | MAPT (0.57) | MAPTMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL3327817 | 0.83 | MAPT (0.56) | MAPTMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL15918696 | 0.83 | MAPT (0.60) | MAPTMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL9061393 | 0.83 | MAPT (0.49) | MAPTMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL5548502 | 0.83 | MEN1 (0.55) | MAPTMEN1KMT2AL3MBTL1POLB | |
| Methane SCHEMBL9392730 | 0.82 | MAPT (0.48) | MAPTMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL8575620 | 0.80 | GPR35 (0.44) | MAPTALDH1A1MAPK1CYP1A2CYP3A4 | |
| SCHEMBL718255 | 0.80 | MAPT (0.74) | MAPTMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL5666638 | 0.80 | MAPT (0.53) | MAPTMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL28835926 | 0.80 | MAPT (0.51) | MAPTMEN1KMT2AL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214576-A1 | Topoisomerase Inhibitors and Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1040108-B1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-6498185-B1 | ENZYME FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6380221-B1 | FOR THERAPY OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6140351-A | FOR TREATING THROMBOSIS | BERLEX LABORATORIES, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1040108-A1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999032477-A1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-01 | — | — | WO | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| US-5332735-A | Antiamnesic activity | ADIR ET COMPAGNIE (FR) | 1994-07-26 | — | — | US | disclosed |
| EP-0086340-B1 | 3-(1H-TETRAZOL-5-YL)-4(3H)-QUINAZOLINONES | THE DOW CHEMICAL COMPANY (US) | 1986-04-02 | — | — | EP | disclosed |
| US-4419357-A | 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones | THE DOW CHEMICAL COMPANY (US) | 1983-12-06 | — | — | US | disclosed |
| EP-0086340-A1 | 3-(1H-tetrazol-5-yl)-4(3H)-quinazolinones | THE DOW CHEMICAL COMPANY (US) | 1983-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214576-A1 | Topoisomerase Inhibitors and Prodrugs | TOP2A, TOP1, TOP2B | MAPT 2510/4885MEN1 2997/4885KMT2A 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.